PRA Opens New Facility in Swansea, Wales
PRA’s new Welsh home office was officially opened today by Edwina Hart AM MBE OStJ, Minister for the Economy, Science and Transport, who announced the expansion is being supported with £1.29 million business finance from the Welsh Government.
“A number of other locations were under consideration for this important expansion project so I am delighted that support from the Welsh Government helped secure it for Wales,” said Mrs. Hart. “This investment is particularly welcome as PRA is a strategically important company within the Life Sciences sector – one of our priority economic sectors with high growth potential.” She added that the expansion will create a significant number of highly-skilled jobs across a range of disciplines over the next three years and reaffirms PRA’s commitment to Wales.
Steve Powell, PRA Executive Vice President, Clinical Informatics and Late Phase Services, said, “We are delighted to officially open our expanded location in Swansea. The new site has received substantial funding from the Welsh government which will mean significant job creation and support for the local economy. As a leading CRO, we are committed to the growth of our Swansea team and to transforming clinical trials across all phases of drug development; the new building and jobs demonstrates PRA’s commitment to offering a more dynamic service to our customers, both locally and internationally.”
PRA, headquartered in North Carolina in the United States, currently employs more than 5,000 employees in over 50 global offices, with the Swansea operation currently providing 100 Clinical Informatics and administration staff who collect, analyze and interpret data from clinical trials. The planned expansion will double the size of the office and ultimately employ close to 200 people in the Swansea area.
Formerly based in Matrix Court, Swansea, PRA moved to Llys Tawe on Swansea’s SA1 development. The move supports PRA's key strategic objective of creating seamless logistics from data collection through information submission for its global customer base.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025